Kura Oncology, Inc. - Common Stock (KURA)

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

These two healthcare growth stocks could have a lot more room to run.

Instead of seeking a takeover, the company inked a deal worth up to $1.53 billion for its lead asset.

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position.

KURA stock results show that Kura Oncology missed analyst estimates for earnings per share the first quarter of 2024.

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

The company just released promising results for its acute myeloid leukemia treatment.

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales

Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100% (5/5), including four patients with NPM1-m acute myeloid leukemia (AML) and one patient with KMT2A-r AML.